Metabolic
Tirzepatide
Dual GIP/GLP-1 Receptor Agonist
Scientific Overview
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist studied for type 2 diabetes and obesity.
Mechanism focus: Simultaneous GIP and GLP-1 receptor engagement amplifies incretin signaling relevant to insulin secretion, appetite regulation, and adipose/energy metabolism.
Research Use Cases
- Dual-incretin receptor pharmacology
- Obesity intervention model comparisons (SURMOUNT)
- Head-to-head incretin agonist studies (SURPASS vs semaglutide)
- Metabolic syndrome biomarker panels
Use-Case Study Notations
- Case-study notation: SURPASS-2 compared tirzepatide with semaglutide for glycemic endpoints in type 2 diabetes.
- Case-study notation: SURMOUNT-1 evaluated once-weekly tirzepatide for obesity treatment endpoints.
- Dual-agonist design requires careful peptide identity testing (MS/HPLC).
Selected Studies (English, PubMed)
Five peer-reviewed sources indexed on PubMed. Links open the PubMed record for verification.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes — PubMed 34170647
- Tirzepatide Once Weekly for the Treatment of Obesity — PubMed 35658024
- Tirzepatide for Obesity Treatment and Diabetes Prevention — PubMed 39536238
- Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management — PubMed 36750526
- Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program — PubMed 36478180
Related compounds
Research Use Only. This page is educational and intended for laboratory research context. Products are not for human consumption and are not intended to diagnose, treat, cure, or prevent any disease.